EICHOR
● Active Not Recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Condition: Atherosclerotic Cardiovascular Disease · Sponsor: Novartis Pharmaceuticals
About this study
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (989)
| UAB St Vincents | Birmingham, Alabama, United States | — |
| Eastern Shore Research Institute | Fairhope, Alabama, United States | — |
| G and L Research LLC | Foley, Alabama, United States | — |
| Alaska Heart and Vascular | Anchorage, Alaska, United States | — |
| Mercy Gilbert Medical Center | Gilbert, Arizona, United States | — |
| Cardiovascular Associates of Mesa | Mesa, Arizona, United States | — |
| Elite Clinical Studies | Phoenix, Arizona, United States | — |
| HonorHealth Heart Group Deer Valley | Scottsdale, Arizona, United States | — |
| Clinical Research Inst of Arizona | Sun City West, Arizona, United States | — |
| Pima Heart And Vascular Clin Rch | Tucson, Arizona, United States | — |
| ARcare Center for Clinical Research | Little Rock, Arkansas, United States | — |
| Arkansas Clinical Research | Little Rock, Arkansas, United States | — |
+ 977 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.